Viridian Therapeutics, Inc. VRDN Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s other accrued liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported other accrued liabilities of $568K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s other accrued liabilities increased by 8.6% year-over-year, from $523K to $568K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s other accrued liabilities?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s other accrued liabilities has grown at a 36.1% compound annual growth rate (CAGR), from $523K to $2.44M.